NCT07260305 2025-12-03
A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients
Kangabio AUSTRALIA LTD PTY
Phase 1 Recruiting
Clinical Trials
11 trialsNCT03478488 2025-05-29
KN035-BTC
3D Medicines
Phase 3 Active not recruiting
NCT05112991 2025-05-29
Study of Envafolimab Alone or With Lenvatinib in Patients With Advanced Endometrial Cancer
3D Medicines
Phase 2 Recruiting
NCT06074497 2025-02-07
This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy with Envafolimab in Patients with Advanced or Metastatic Solid Tumors.
Kangabio AUSTRALIA LTD PTY
Phase 1 Active not recruiting
NCT04910386 2024-08-14
Multicenter Phase 2 Study of Envafolimab in Biliary Tract Cancers
3D Medicines
Phase 2 Not yet recruiting
NCT05068427 2024-08-07
Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.
Chipscreen Biosciences, Ltd.
Phase 2 Completed
NCT04480502 2024-05-17
ENVASARC
Tracon Pharmaceuticals Inc.
Phase 2 Active not recruiting
NCT05448820 2023-09-21
YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma
Tracon Pharmaceuticals Inc.
Phase 1/2 Unknown
NCT03101488 2022-03-03
Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors
3D Medicines
Phase 1 Completed
NCT03248843 2022-02-08
A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors
3D Medicines
Phase 1 Completed
NCT02827968 2021-06-02
Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors
3D Medicines
Phase 1 Completed